Close X
Saturday, November 2, 2024
ADVT 
National

A look at the rare blood clot condition VIPIT

Darpan News Desk The Canadian Press, 29 Mar, 2021 08:56 PM
  • A look at the rare blood clot condition VIPIT

Federal officials limited the use of Oxford-AstraZeneca's COVID-19 vaccine Monday while it announced an investigation into reported links to a rare blood clot condition known as VIPIT.

The National Advisory Committee on Immunization says the vaccine should not be used by people younger than age of 55, while Health Canada has issued guidelines around what to look for if you suspect you have had an adverse reaction.

Here’s a look at this rare condition.

WHAT IS VIPIT?

VIPIT stands for: Vaccine-Induced Prothrombotic Immune Thrombocytopenia. According to NACI, it is associated with the development of antibodies that "activate" platelets, which stimulate the formation of blood clots.

HOW DANGEROUS IS VIPIT?

The case fatality of VIPIT is approximately 40 per cent, however that may decrease with increased awareness and early treatment.

HOW COMMON IS THIS ADVERSE REACTION?

It’s not clear how common this happens after vaccination but the European Medicines Agency said March 18 it was originally believed to occur once per 1,000,000 people vaccinated with the AstraZeneca vaccine. However, a higher rate of 1 per 100,000 was reported in Germany.

WHO DOES THIS AFFECT?

So far, cases have largely been among women younger than age 55 and mostly emerged between four and 16 days after vaccination. However, a brief for Ontario’s COVID-19 advisory group notes many European countries used more of their initial AstraZeneca doses in women under age 55, which may have skewed the results.

The provincial science table experts add that VIPIT does not appear to be more common in people who have had blood clots before, have a family history of blood clots, have a low platelets, or pregnant women.

ARE THERE KNOWN CASES IN CANADA LINKED TO THE ASTRAZENECA VACCINE?

No.

WHAT ARE THE WARNING SIGNS?

Experts say to look for the following symptoms between four and 20 days after vaccination: a severe headache that does not go away; a seizure; difficulty moving part of your body; new blurry vision that does not go away; difficulty speaking; shortness of breath; chest pain; severe abdominal pain; new severe swelling, pain, or colour change of an arm or a leg.

MORE National ARTICLES

In-person gatherings important, says church lawyer

In-person gatherings important, says church lawyer
Chief Justice Christopher Hinkson said during a hearing on Tuesday people are still free to hold and express religious views and it's the safety of those who are gathering that's at issue.

In-person gatherings important, says church lawyer

One Arrested After Gasoline Poured On Tent, Occupants Threatened

One Arrested After Gasoline Poured On Tent, Occupants Threatened
The tent was occupied by a woman and her dog at the time of the incident. Patrol officers attended and located the suspect in Cecilia Ravine Park.

One Arrested After Gasoline Poured On Tent, Occupants Threatened

A look at the Oxford-AstraZeneca vaccine

A look at the Oxford-AstraZeneca vaccine
On the one hand, Health Canada says Oxford-AstraZeneca’s vaccine has been deemed safe for seniors and points to emerging real-world data that shows it can protect older citizens against symptomatic infection.

A look at the Oxford-AstraZeneca vaccine

5.6M in funding for drug-dispensing machines

5.6M in funding for drug-dispensing machines
The machines, called MySafe, are similar to ATMs and allow drug users at risk of overdose to get hydromorphone pills dispensed to them after their palm has been scanned.

5.6M in funding for drug-dispensing machines

Ontario waits for guidance as B.C. delays 2nd dose

Ontario waits for guidance as B.C. delays 2nd dose
Alberto Martin, a University of Toronto immunology professor, says a published clinical trial showed the first dose of the Pfizer-BioNTech vaccine provided 60 per cent protection, but B.C. may have access to new or unpublished data.

Ontario waits for guidance as B.C. delays 2nd dose

Mounties who shot at other RCMP won't face charges

Mounties who shot at other RCMP won't face charges
The Serious Incident Response team concludes the officers who fired their guns had been told the killer was driving a replica police vehicle and was wearing an orange vest, giving them grounds to believe the officer standing beside a patrol car was the murderer.

Mounties who shot at other RCMP won't face charges